5 Top Growth Stocks to Buy the Dip

 bullish.beats
 
  bullish.beats
 
Follow  Message
 
 
 
Streaking.Winners tracks stocks achieving consecutive gains, focusing on consistent performers and market momentum to keep investors informed.
 

•  06 Dec 2025
 

•   DDOG  
   
  0.00%
•   HALO  
   
  0.00%
•   ORCL  
   
  0.00%
•   SNOW  
   
  0.00%

$ORCL Oracle Corporation is trading at $217.58, down a substantial 37% from its 52-week high of $345.72. That's a massive correction for a company that just a few months ago was riding high on artificial intelligence enthusiasm. The stock now sits well below its 50-day moving average of $261.98, and the RSI reading of 43.63 suggests the selling pressure may be approaching exhaustion. What happened to Oracle? Nothing fundamentally broken, actually. The company delivered strong earnings back in September that showed explosive growth in its AI cloud business. Major enterprises are rushing to build AI infrastructure, and Oracle is one of the key providers. The pullback appears to be more about market sentiment and profit-taking than any deterioration in the business itself. With volume running above average at 23.82 million shares versus the typical 21.39 million, there's clearly heightened interest in the stock at these levels.

The timing matters here. Oracle reports Q2 earnings on December 10th, which is right around the corner. Wall Street will be focused on whether the AI cloud momentum is accelerating or if there are signs of softness. For traders willing to take on some event risk, the current price could represent an attractive entry ahead of what might be a positive surprise. The risk-reward setup looks reasonable given how far the stock has fallen.

$SNOW Snowflake presents a different but equally interesting situation. The cloud data platform dropped 11% in a single day recently despite posting 29% revenue growth in its Q3 report. The stock closed at $228.79, about 18% below its 52-week high of $280.67. This looks like a classic case of "sell the news" where the market reaction didn't match the fundamental performance. What spooked investors? A brief service outage impacted revenues slightly, and traders used that as an excuse to take profits after a strong run. But step back and look at the bigger picture. Snowflake is growing at nearly 30% annually in a massive market. The position in cloud data warehousing remains strong, and the AI-driven demand for data analytics is only accelerating. Management provided solid guidance, suggesting they see continued growth ahead.

The technical setup on Snowflake is compelling. The RSI sits at 36.76, firmly in oversold territory. Volume spiked to 11.62 million shares, more than double the average of 4.97 million, which often signals capitulation selling. The stock is approaching its 50-day moving average of $245.84, which could serve as resistance if a bounce materializes. For traders who believe in the data analytics megatrend, this pullback might be the opportunity they've been waiting for.

$DDOG Datadog at $151.41 offers a slightly different profile. This observability platform provider is down roughly 25% from its 52-week high of $201.69, but unlike the others, it's showing a sideways trend rather than a clear downtrend. That's actually encouraging because it suggests consolidation rather than panic. What makes Datadog interesting is its technical positioning. The stock is still trading above both its 50-day moving average of $157.81 and its 200-day moving average of $131.75. That's a sign of underlying strength even during the pullback. The RSI of 36.08 indicates approaching oversold conditions without the severe selling seen in some peers. Volume has picked up to 5.89 million from an average of 4.91 million, showing increased trader interest.

Datadog business is deeply embedded in the cloud infrastructure that modern companies depend on. As organizations deploy more AI applications and complex microservices, the need for comprehensive monitoring and observability grows. This isn't a speculative bet on future technology. It's a play on infrastructure that's already essential and becoming more critical every quarter. The current pause in the stock price could be an opportunity to establish positions before the next leg higher.

$HALO Halozyme Therapeutics might surprise you on a list of growth stocks. Healthcare doesn't always get the same attention as technology, but this company deserves a closer look. Trading at $63.33, down from a 52-week high of $79.50, Halozyme is generating substantial free cash flow while maintaining leadership in subcutaneous drug delivery technology. The ENHANZE platform that Halozyme has developed allows drugs traditionally given intravenously to be administered subcutaneously instead. This improves convenience for patients and reduces healthcare costs. More importantly, the company has partnerships with major pharmaceutical firms, creating recurring revenue as partner drugs gain market adoption. This isn't a binary biotech bet. It's a steady business model with visible cash generation.

The technical picture on Halozyme shows an RSI of 32.88, which is deeply oversold. The stock is trading near its 200-day moving average support at $62.85, a level that has historically provided buying interest. While the trend is technically down, the combination of oversold conditions and strong fundamentals creates an asymmetric setup. For traders looking to diversify beyond pure technology plays, Halozyme offers growth with more defensive characteristics.

When approaching these dip-buying opportunities, think about your own trading style and risk tolerance. Conservative traders might start with partial positions, planning to add more if the stocks dip further or after positive catalysts emerge. Using the 50-day moving averages as initial price targets and 200-day moving averages as stop-loss levels provides a structured approach.

More aggressive traders might look at the deeply oversold RSI readings as signals for near-term bounces. Options strategies like bull put spreads can define risk while capturing upside potential. The key is matching your strategy to your conviction level and time horizon.

For longer-term investors, dollar-cost averaging into these positions over several weeks could smooth out the volatility while building strategic holdings. The worst entries often come from trying to perfectly time the bottom. Spreading purchases over time reduces that pressure.

Of course, no trading strategy is without risk. The current market environment has its challenges. Interest rate policies continue to create uncertainty. Sector rotation could see more money flowing out of growth stocks and into value plays. Each of these companies faces its own competitive pressures and execution risks. Technical damage can persist longer than fundamentals would suggest it should.

The discipline around position sizing and stop-losses matters more than ever. Even the best setups can fail in the short term. Protecting capital when you're wrong is just as important as maximizing gains when you're right. This isn't about being stubborn or hoping for the best. It's about having a plan and sticking to it.

What makes these five stocks compelling right now is the combination of technical oversold conditions, fundamental quality, and visible catalysts. Oracle has its earnings on the immediate horizon. Snowflake is working through a temporary setback after strong growth. Datadog is consolidating above key support levels. Halozyme is generating cash while trading at depressed valuations.

These aren't speculative lottery tickets. They're established companies with real businesses, real revenues, and real growth trajectories. The market has temporarily repriced them lower, creating potential opportunities for those willing to look past the near-term noise.

The recent selloffs have created technical setups that historically favor patient buyers. When RSI readings reach oversold territory and prices approach key moving average support levels, rebounds often follow. Not immediately, and not in a straight line, but over time. That's the nature of buying the dip. You're positioning ahead of the crowd, which means you might feel uncomfortable initially.

Remember that buying the dip isn't about catching falling knives or blindly buying every stock that's down. It's about identifying quality businesses experiencing temporary setbacks and positioning yourself strategically. It's about distinguishing between price action and value. Sometimes they diverge significantly, and that's where opportunities emerge.

These 5 stocks fit that profile for the week ahead. Each offers a different angle on growth, from Oracle AI cloud transformation to Snowflake data platform dominance, Datadog observability moat, and Halozyme healthcare innovation. Together, they represent multiple paths to potential upside.

As always, this analysis is for educational purposes and represents one perspective on current market opportunities. Your own research, risk assessment, and financial situation should guide your decisions. But if you're looking for quality growth stocks that have pulled back and might be setting up for their next moves higher, these five names deserve your attention this week.

View All Headlines